Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 03, 2025 18:10 ET | Source: Biogen Inc.

Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer’s Disease at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025

Long-term LEQEMBI treatment suggests potential to delay disease progression from Mild Cognitive Impairment (MCI) to moderate Alzheimer’s disease by up to 8.3 years in low-amyloid group who started...
December 02, 2025 16:40 ET | Source: Biogen Inc.

New Data Presented at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF

TOKYO and CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge,...
December 02, 2025 09:00 ET | Source: Eagleview

Eagleview's Inaugural AI Impact and Adoption Report Unveils the State of AI in Geospatial Workflows

Rochester, NY, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Eagleview, a leading provider of aerial imagery and intelligence, announces the release of its inaugural AI Impact and Adoption Report, a...
December 02, 2025 07:02 ET | Source: Ventyx Biosciences, Inc.

Ventyx Provides Clinical and Corporate Updates

Strengthening our Advisory Board with addition of Mark McKenna as Strategic Advisor and Peter Libby, MD as a Clinical AdvisorExpanding the Phase 2 recurrent pericarditis study into Canada, EU and the...
November 27, 2025 19:30 ET | Source: Biogen Inc.

Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer’s Disease in Japan

TOKYO and CAMBRIDGE, Mass., Nov. 27, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge,...
November 25, 2025 07:30 ET | Source: Biogen Inc.; Eisai Co., Ltd.

Eisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status

TOKYO and CAMBRIDGE, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge,...
November 20, 2025 06:00 ET | Source: Raise Your Hand Texas

Raise Your Hand Texas Briefs Legislative Offices on Proposed New Endowment for Texas Public Schools

Raise Your Hand Texas wishes to collaborate with the 90th Legislature to establish a new endowment that is an increasing source of public school funding.
November 19, 2025 09:00 ET | Source: Eagleview

Eagleview Launches an Early Access, Free Imagery API Trial to Power the Next Generation of Geospatial Applications

Rochester, NY, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Eagleview, a leader in ultra-high-resolution aerial imagery and geospatial intelligence, today announced a major expansion of its developer...
November 19, 2025 08:15 ET | Source: Precedence Research

Meat Market Size Worth USD 2.30 Trillion by 2034 | Towards FnB

Ottawa, Nov. 19, 2025 (GLOBE NEWSWIRE) -- The global meat market size was valued at USD 1.15 trillion in 2024 and is predicted to increase from USD 1.23 trillion in 2025 to reach around USD 2.30...
November 13, 2025 18:30 ET | Source: Biogen Inc.

“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in the United Kingdom

TOKYO and CAMBRIDGE, Mass., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge,...